Merck and Gilead provide update on Phase 3 KEYNOTE-D46/EVOKE-03 studymerck.com
Gilead and Merck announced positive topline results from two Phase 3 studies evaluating islatravir/lencapavir, a once-weekly oral HIV treatmentbusiness wire
Gilead’s lung cancer bid for Trodelvy hit, but HIV studies give better newsFirstward Pharma
Will an HIV win and a lung cancer loss in trials reset Merck’s (MRK) risk reward story?yahoo finance
Gilead and Merck’s once-weekly HIV combo pill works in trialsbloomberg.com
